Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN3470-3471-3479 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 1 or placebo |
| Cohort 2 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 2 or placebo |
| Cohort 3 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 3 or placebo |
| Cohort 4 | EXPERIMENTAL | REGN3470-3471-3479 dosing level 4 or placebo |
| Name | Type | Description |
|---|---|---|
| REGN3470-3471-3479 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: 1. Healthy man or woman between the ages of 18 and 60 2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive 3. Willing and able to comply with clinic visits and study-related procedures 4. Provide signed informed consent 5. Able to understand and complete study-related que...
REGN3470-3471-3479 is an investigational small molecule therapeutic being developed by Regeneron Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers to assess its safety, tolerability, and pharmacokinetics. The specific disease indications for which it is being developed have not been disclosed.
REGN3470-3471-3479 is being developed by Regeneron Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker symbol REGN. Regeneron is the sponsor of the clinical program for this asset.
REGN3470-3471-3479 is in Phase 1 clinical development. It has completed one Phase 1 trial in healthy adult volunteers. There are currently no active trials of REGN3470-3471-3479 listed.
REGN3470-3471-3479 has been evaluated in one completed Phase 1 trial, NCT02777151, titled "Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers." The trial enrolled 24 participants in the United States and was randomized, double-blind, and controlled.
No, REGN3470-3471-3479 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in healthy volunteers. It remains in clinical development and has not received marketing authorization for any indication.